Standard BioTools Q3 2024 GAAP EPS $(0.07) Beats $(0.09) Estimate, Sales $44.969M Beat $40.998M Estimate
LaBranche & Co -7.61% Post
LaBranche & Co LAB | 1.70 1.70 | -7.61% 0.00% Post |
Standard BioTools (NASDAQ:
LAB) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 22.22 percent. The company reported quarterly sales of $44.969 million which beat the analyst consensus estimate of $40.998 million by 9.68 percent. This is a 77.27 percent increase over sales of $25.367 million the same period last year.